Calico Life Sciences
Calico Life Sciences is an Aging Drug Discovery company founded in 2013 and based in South San Francisco, United States.
Calico Life Sciences is a South San Francisco biotech founded in 2013 by Alphabet (then Google) together with former Genentech chairman and CEO Arthur D. Levinson, who serves as CEO. Operating as an Alphabet subsidiary rather than an independent startup, Calico focuses on the fundamental biology of aging and translating those insights into therapeutics for age-related disease. From 2014 it ran a multibillion-dollar drug-discovery collaboration with AbbVie that produced more than 20 early-stage programs across neurodegeneration and immuno-oncology and advanced three targets into the clinic. AbbVie terminated that partnership in November 2025 after a Phase II/III ALS candidate failed, with associated layoffs; Calico continues as an Alphabet-backed research organization.
The highest-profile, deepest-pocketed corporate bet on the basic biology of aging, backed by Alphabet and led by a biotech industry legend.
calicolabs.com ↗·Aging Drug Discovery·
United States·private 
